# Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis

Study · id `cardio:ct-nct01254552` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01254552](<https://clinicaltrials.gov/study/NCT01254552>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01254552

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 351 participants.

## Technical summary

Registry record NCT01254552. Allocation not applicable; no masking; primary purpose diagnostic. Start 2010-08 (actual); primary completion 2011-09 (actual). Results posted on 2019-05-31.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 351 participants (enrolled count; ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Started: 2010-08 (actual) (ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Primary completion: 2011-09 (actual) (ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Completion: 2016-10 (actual) (ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Results first posted: 2019-05-31 (ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01254552, source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01254552-2019-05-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
- Acronym: ACCREDIT
- Condition: Type 2 Diabetes Mellitus
- Condition: Coronary Atherosclerosis
- Intervention (Drug): iobitridol
- Intervention (Drug): gadoterate meglumine
- Lead sponsor: Guerbet
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Guerbet (`cardio:org-guerbet`)

## Provenance

Content hash: ce7a19b90350161c0d21c4df6e93f1c0e67281868b89c0ac7aa60028f92027e2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
